Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

46 THE PREMENSTRUAL SYNDROMES
35. Banerjee N, Roy KK, Takkar D. Premenstrual dysphoric disorder –
a study from India. Int J Fertil Womens Med 2000; 45:342–4.
36. Hsiao MC, Liu CY, Chen KC et al. Characteristics of women
seeking treatment for premenstrual syndrome in Taiwan. Acta
Psychiatr Scand 2002; 106:150–5.
37. Sveindottir H. Prospective assessment of menstrual and premenstrual
experiences of Icelandic women. Health Care Women Int
1998; 19:71–82.
38. van den Akker OB, Eves FF, Service S et al. Menstrual cycle
symptom reporting in three British ethnic groups. Soc Sci Med
1995; 40:1417–23.
39. Hasin M, Dennerstein L, Gotts G. Menstrual cycle related complaints:
a cross-cultural study. J Psychosom Obstet Gynaecol
1988; 9:35–42.
40. Freeman EW. Effects of antidepressants on quality of life in
women with premenstrual dysphoric disorder. Pharmacoeconomics
2005; 23:433–44.
41. Rapaport MH, Clary C, Fayyad R et al. Quality-of-life impairment
in depressive and anxiety disorders. Am J Psychiatry 2005;
162:1171–8.
42. Barnard K, Frayne SM, Skinner KM et al. Health status among
women with menstrual symptoms. J Womens Health 2003;
12:911–19.
43. Winter EJ, Ashton DJ, Moore DL. Dispelling myths: a study of
PMS and relationship satisfaction. Nurse Pract 1991; 16:34,
7–40,45.
44. Hardie EA. PMS in the workplace: dispelling the myth of cyclic
dysfunction. J Occup Organiz Psychol 1997; 70:97–102.
45. Kraemer GR, Kraemer RR. Premenstrual syndrome: diagnosis
and treatment experiences. J Womens Health 1998; 7:893–907.
46. Singh BB, Berman BM, Simpson RL et al. Incidence of premenstrual
syndrome and remedy usage: a national probability sample
study. Altern Ther Health Med 1998; 4:75–9.
47. Ryser R, Feinauer LL. Premenstrual syndrome and the marital
relationship. Am J Fam Ther 1992; 20:179–90.
48. Hallman J, Georgiev N. The premenstrual syndrome and absence
from work due to illness. J Psychosom Obstet Gynaecol 1987;
6:111–19.
49. Corney RH, Stanton R. A survey of 658 women who report
symptoms of premenstrual syndrome. J Psychosom Res 1991;
35:471–82.
50. Campbell EM, Peterkin D, O’Grady K et al. Premenstrual symptoms
in general practice patients. Prevalence and treatment.
J Reprod Med 1997; 42:637–46.
51. Kuan AJ, Carter DM, Ott FJ. Distress levels in patients with
premenstrual dysphoric disorder. Can J Psychiatry 2002;
47:888–9.
52. Gallant SJ, Popiel DA, Hoffman DM et al. Using daily ratings to
confirm premenstrual syndrome/late luteal phase dysphoric disorder.
Part II. What makes a “real” difference? Psychosom Med
1992; 54:167–81.
53. Kuczmierczyk AR, Labrum AH, Johnson CC. Perception of
family and work environments in women with premenstrual syndrome.
J Psychosom Res 1992; 36:787–95.
54. Frank B, Dixon DN, Grosz HJ. Conjoint monitoring of symptoms
of premenstrual syndrome: impact on marital satisfaction. J Couns
Psychol 1993; 40:109–14.
55. Chawla A, Swindle R, Long S et al. Premenstrual dysphoric disorder:
is there an economic burden of illness? Med Care 2002;
40:1101–12.
56. Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a
new measure to assess treatment effects. Psychopharmacol Bull
1997; 33:13–16.
57. Borenstein JE, Dean BB, Endicott J et al. Health and economic
impact of the premenstrual syndrome. J Reprod Med 2003;
48:515–24.
58. Dean BB, Borenstein JE. A prospective assessment investigating
the relationship between work productivity and impairment with
premenstrual syndrome. J Occup Environ Med 2004; 46:649–56.
59. Steiner M, Steinberg S, Stewart D et al. Fluoxetine in the treatment
of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual
Dysphoria Collaborative Study Group. N Engl J Med 1995;
332:1529–34.
60. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome:
the development of research diagnostic criteria and new
rating scales. Acta Psychiatr Scand 1980; 62:177–90.
61. Steiner M, Brown E, Trzepacz P et al. Fluoxetine improves functional
work capacity in women with premenstrual dysphoric disorder.
Arch Womens Ment Health 2003; 6:71–7.
62. Cohen LS, Miner C, Brown EW et al. Premenstrual daily fluoxetine
for premenstrual dysphoric disorder: a placebo-controlled,
clinical trial using computerized diaries. Obstet Gynecol 2002;
100:435–44.
63. Miner C, Brown E, McCray S et al. Weekly luteal-phase dosing
with enteric-coated fluoxetine 90 mg in premenstrual dysphoric
disorder: a randomized, double-blind, placebo-controlled clinical
trial. Clin Ther 2002; 24:417–33.
64. Su TP, Schmidt PJ, Danaceau MA et al. Fluoxetine in the treatment
of premenstrual dysphoria. Neuropsychopharmacology 1997;
16:346–56.
65. Yonkers KA, Halbreich U, Freeman E et al. Symptomatic
improvement of premenstrual dysphoric disorder with sertraline
treatment. A randomized controlled trial. Sertraline Premenstrual
Dysphoric Collaborative Study Group. JAMA 1997; 278:983–8.
66. Halbreich U, Bergeron R, Yonkers KA et al. Efficacy of intermittent,
luteal phase sertraline treatment of premenstrual dysphoric
disorder. Obstet Gynecol 2002; 100:1219–29.
67. Pearlstein TB, Halbreich U, Batzar ED et al. Psychosocial functioning
in women with premenstrual dysphoric disorder before
and after treatment with sertraline or placebo. J Clin Psychiatry
2000; 61:101–9.
68. Freeman EW, Rickels K, Sondheimer SJ et al. Continuous or intermittent
dosing with sertraline for patients with severe premenstrual
syndrome or premenstrual dysphoric disorder. Am J
Psychiatry 2004; 161:343–51.
69. Freeman EW, Rickels K, Sondheimer SJ et al. Differential response
to antidepressants in women with premenstrual syndrome/
premenstrual dysphoric disorder: a randomized controlled trial.
Arch Gen Psychiatry 1999; 56:932–9.
70. Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled
release for premenstrual dysphoric disorder: a double-blind,
placebo-controlled trial. Psychosom Med 2004; 66:707–13.
71. Pearlstein TB, Bellew KM, Endicott J et al. Paroxetine controlled
release for premenstrual dysphoric disorder: remission analysis
following a randomized, double-blind, placebo-controlled trial.
Prim Care Companion J Clin Psychiatry 2005; 7:53–60.
72. Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing
with paroxetine controlled release (CR) in the treatment of premenstrual
dysphoric disorder. Am J Obstet Gynecol 2005; 193:
352–60.
73. Freeman EW, Sondheimer SJ, Sammel MD et al. A preliminary
study of luteal phase versus symptom-onset dosing with escitalopram
for premenstrual dysphoric disorder. J Clin Psychiatry
2005; 66:769–73.
74. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new lowdose
oral contraceptive with drospirenone in premenstrual dysphoric
disorder. Obstet Gynecol 2005; 106:492–501.
75. Pearlstein TB, Bachmann GA, Zacur HA et al. Treatment of premenstrual
dysphoric disorder with a new drospirenone-containing
oral contraceptive formulation. Contraception 2005; 72:414–21.
76. Apter D, Borsos A, Baumgartner W et al. Effect of an oral contraceptive
containing drospirenone and ethinylestradiol on general